On March 23, 2009, Oracle announced it has entered into an agreement to acquire Relsys International, Inc. ("Relsys"), a leading global provider of drug safety and pharmacovigilance solutions for the health sciences industry. The transaction is subject to customary closing conditions and is expected to close in the first half of 2009. Until the deal closes, each company will continue to operate independently.
The combination is expected to deliver the only application suite that supports the end-to-end safety processes across clinical development, post-market surveillance and patient care. Pharmaceutical companies, biotech firms, clinical research organizations, medical device manufacturers, health science institutions and government agencies are expected to improve the collection, monitoring and analysis of safety data and help to proactively manage safety risk. Oracle's leading health sciences software suite combined with Relsys's safety and risk management solutions are expected to enable customers to identify safety risks earlier in the development cycle, provide greater transparency into safety reporting and allow companies to better perform post-market surveillance through an integrated and proactive risk management strategy.
Relsys is a leading provider of safety software for the health sciences industry and has a history of developing innovative and integrated products. In addition to their leading adverse events reporting software and advanced safety analytics capabilities, Relsys brings significant domain expertise in delivering safety and risk management solutions to their customers globally. Relsys's management and employees are expected to join Oracle as a part of the Health Sciences Global Business Unit and to continue to develop and deliver focused and leading solutions to customers worldwide.
After the close of the transaction, we expect that Oracle partners will benefit from working with a single vendor to address customer needs for clinical development, drug safety and pharmacovigilance solutions. Partners are expected to leverage the combined, broader footprint, to gain expanded opportunities to provide solutions, and to take advantage of Oracle's worldwide resources and partner ecosystem.
To learn more about the proposed combination of Oracle and Relsys, please visit oracle.com/relsys.
We appreciate your continued support.
Neil de Crescenzo
Senior Vice President and General Manager
Oracle Health Sciences
Group Vice President
Oracle Worldwide Alliances and Channels
The above is for informational purposes only and may not be incorporated into a contract.